A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Colon, Pancreas, LiverColon Cancer, Pancreatic Cancer, Liver Cancer
-
Age: Between 18 Year(s) - 99 Year(s)
-
Gender: Male or Female
-
Other Inclusion Criteria:
- 1) Has a histologically confirmed, unresectable, or metastatic (Stage IV American Joint Committee on Cancer eighth edition) colorectal adenocarcinoma
- 2) Has a locally determined pMMR or not-MSI-H tumor status
- 3) Must have been previously treated with 1 line of therapy including a fluoropyrimidine plus oxaliplatin with or without anti-VEGF mAb or anti-EGFR mAb therapy
You may not be eligible for this study if the following are true:
-
- 1) Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing
- 2) Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease
- 3) HIV-infected participants with a history of Kaposi’s sarcoma and/or Multicentric Castleman's Disease
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.